Drugs / ONO-8577
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03106623 | Apr → Aug 2017 | overactive bladder | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONO-8577 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03106623 ↗ |
| Route | Oral | “Oral administration of ONO-8577 once a daily for 4 weeks” NCT03106623 ↗ |